Cancer group sets PSA test interval at 300,000 annual diagnoses
The American Cancer Society now advises biennial screening for men 50 to 69, a shift from its previous recommendation to discuss testing with doctors.
By Lauren Foster ·

The American Cancer Society issued its first updated prostate cancer screening guidelines in over a decade on Thursday. The new guidance replaces a strategy of shared decision-making with a specific schedule for blood testing.
The Society previously advised men to start conversations about screening with their physicians at certain ages but did not directly recommend the prostate-specific antigen, or PSA, test. That approach mirrored the 2018 guidance from the US Preventive Services Task Force, an independent panel that is currently updating its own recommendations. Health Secretary Robert F. Kennedy Jr. recently replaced two of that task force's leaders.
Under the new rules, men aged 50 to 69 should receive a PSA test every two years. Men at high risk, which includes Black men and those with a strong family history, should begin annual testing at age 45. The Society cites stronger evidence that PSA testing lowers deaths and advanced-stage diagnoses. It acknowledges the test produces false positives, but states that combining it with other methods reduces the harms of unnecessary procedures.
Prostate cancer affects more than 300,000 men in the United States this year. About 36,000 are expected to die from the disease. Black men are twice as likely to die from prostate cancer as white men. In 2023, roughly 40 percent of men aged 55 to 69 had a PSA test in the prior year. The rate for Black men was approximately 33 percent.
Men aged 70 to 74 should make individualized decisions about continuing screening. The Society states the balance of benefits and harms remains uncertain for that group. Most men 75 and older should not be screened because treatment harms are more likely to outweigh benefits. Those with elevated PSA levels of 3 ng/mL or higher for ages 45 to 69, or 6.5 ng/mL or higher for ages 70 to 74, must undergo repeat testing between two weeks and three months. Confirmed elevated levels should lead to magnetic resonance imaging and biomarker tests before a biopsy.
Dr. William Dahut, the Society's chief scientific officer, said the goals are to decrease metastatic diagnoses and death while minimizing harm. He noted that using imaging and biomarkers allows doctors to offer active surveillance for low-risk cancer instead of immediate treatment. Dr. Adam Feldman, a urologic oncologist at Mass General Brigham Cancer Institute, said the guidelines highlight the value of early detection. He was not involved in creating the guidance.
Dr. Glen McWilliams, a urologic oncologist and trustee of the National Medical Association, suggested Black men with relatives diagnosed at younger ages should consider screening as early as 35. He noted that many patients are diagnosed with aggressive prostate cancer before age 40. In October, Boston Medical Center launched a mobile van to provide free PSA tests and education in local communities. Dr. Toby Chai, chief of urology at BMC, said the goal is to provide information so men can understand the benefits of testing.






